anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention provides a method and apparatus for obtaining hierarchical information of planar data. The method comprises mapping at least one data item from a same data set in the planar data to at least one node in a tree structure formed by a structured terminology system. The method also comprises obtaining at least one sub tree structure in the tree structure, each of the at least one sub tree structure taking the at least one node as all of its leaf node. The method also comprises selecting a target tree structure from the at least one sub tree structure and obtaining hierarchical information in the target tree structure. An apparatus corresponding to the above method is also provided. With the above method and apparatus, hierarchical information of data items may be obtained from planar organized data to facilitate subsequent and further analysis and management.
These subjects will be assigned to first receive prebiotics (Prebiotin Prebiotic Fiber Stick Pac) for 6 weeks. Then after a 6 week wash-out period, subjects will take probiotics (Visbiome®) for 6 weeks (followed again by a 6 week washout period).
Those with severe symptoms (indicated by an ICG-r score \>25) will be notified that their symptoms are considered to be severe, with a suggestion to attend the virtual support groups. A recent meta-analysis of psychological interventions for grief found higher effect sizes in studies of participants who were \>6 months post-loss, and those with higher baseline symptom levels. However, no participant in our study will be randomized to any treatment assignment, and the decision to attend the VSG will be left to the family members.
BACKGROUND: Primary ovarian insufficiency (POI) is defined as cessation of ovarian function before the age of 40 years, which is characterized by amenorrhoea, infertility, elevated gonadotrophin level and sex-steroid deficiency. The phenotypes of POI are heterogeneous, including isolated and syndromic forms. Perrault syndrome (PS), characterized by sensorineural hearing loss (SNHL) and ovarian dysfunction before 40 years in females, is one type of syndromic POI. Genetic defects play a vital role in the pathogenesis of POI.
METHODS AND RESULTS: To illustrate the genetic causation of Perrault syndrome, we performed whole exome sequencing (WES) in one pedigree with the disease, and identified a novel homozygous mutation in TWNK (c.1388G > A, p.R463Q). TWNK encodes a hexameric DNA helicase in mitochondria and plays a critical role in mtDNA replication. In order to determine the effect of the novel mutation on the mitochondrial function, we generated immortalized cell lines by infecting lymphocytes from the family members with EB virus in vitro. Functional studies found that TWNK p.R463Q impaired mtDNA replication and the respiration potential of mitochondria, while the ROS level remains unaffected.
CONCLUSION: Our study provided evidence that TWNK mutation impaired the ovarian function by dysfunctional mitochondria. Moreover, considering the patients here presented POI onset earlier than SNHL, specific variants localizing in different locus of TWNK might induce heterogeneous phenotypes, indicating that the genetic screening of patients with POI would be useful for early recognition of other disease or other phenotypes of syndromic POI.
One aspect of the present invention comprises a vaccine for the prevention of disease caused by feline infectious peritonitis virus (FIPV). Such vaccine comprises FIP viral precursor immunogens derived from in vitro produced cells persistently infected with FIPV. Preferred in the production of viral immunogens forming the vaccine of the present invention is the Crandall Feline Kidney (CrFK) cell line. Thus, a second aspect of the invention comprises FIP-infected Crandall Feline Kidney cell line, deposited at the American Type Culture Collection (ATCC), Rockville, MD, on Sep. 23, 1992, and granted Accession No. CRL11137. A third aspect of the invention relates to a method of producing FIP viral precursor immunogens, which comprises culturing in vitro FIP-persistent infected cells in a serum-containing growth medium, subsequently transferring and maintaining said cultured cells in a serum-free medium under conditions and for a time adequate to accumulate FIP viral precursor immunogens shed from said cells, and then separating the cells from the supernatant containing the vital precursor immunogens. The supernatant containing the FIP viral precursor immunogens is blended with a pharmaceutically-acceptable adjuvant in order to form the FIP vaccine disclosed herein.
This study aimed to identify and validate a 9-gene signature for predicting overall survival (OS) in glioma patients. Analysis of multiple gene expression datasets led to the identification of 135 candidate genes associated with OS in glioma patients. Further analysis revealed that IGFBP2, PBK, NRXN3, TGIF1, DNAJA4, and LGALS3BP were identified as risk factors for OS, while ENAH, PPP2R2C, and SPHKAP were found to be protective factors. Multifaceted validation using different databases confirmed their differential expression patterns in glioma tissues compared to normal brain tissue. By utilizing LASSO regression and multivariate Cox regression analysis, a risk score was developed based on the expression levels of the 9 crucial genes. The risk score showed a significant correlation with OS in both training and validation cohorts and yielded superior predictive accuracy compared to individual gene expression. Moreover, a predictive nomogram incorporating the risk score, WHO grade, age, IDH mutation, and 1p/19q co-deletion was constructed and validated, which exhibited high predictive capabilities for survival rates at different time points. Enrichment analysis revealed the involvement of extracellular matrix-related pathways and immune system signaling in glioma prognosis. Furthermore, the risk score showed a strong correlation with immune cell infiltration and immune checkpoint expression, suggesting its potential role in the tumor immune microenvironment. In conclusion, our study provides a robust 9-gene signature and a predictive nomogram for evaluating the prognosis of glioma patients, offering valuable insights into personalized treatment strategies.
Profound functional switch of key regulatory factors may play a major role in homeostasis and disease. Dysregulation of circadian rhythm (CR) is strongly implicated in cancer with mechanisms poorly understood. We report here that the function of REV-ERBα, a major CR regulator of the orphan nuclear receptor subfamily, is dramatically altered in tumors in both its genome binding and functional mode. Loss of CR is linked to a functional inversion of REV-ERBα from a repressor in control of CR and metabolic gene programs in normal tissues to a strong activator in different cancers. Through changing its association from NCoR/HDAC3 corepressor complex to BRD4/p300 coactivators, REV-ERBα directly activates thousands of genes including tumorigenic programs such as MAPK and PI3K-Akt signaling. Functioning as a master transcriptional activator, REV-ERBα partners with pioneer factor FOXA1 and directly stimulates a large number of signaling genes, including multiple growth factors, receptor tyrosine kinases, RASs, AKTs, and MAPKs. Moreover, elevated REV-ERBα reprograms FOXA1 to bind new targets through a BRD4-mediated increase in local chromatin accessibility. Pharmacological targeting with SR8278 diminishes the function of both REV-ERBα and FOXA1 and synergizes with BRD4 inhibitor in effective suppression of tumorigenic programs and tumor growth. Thus, our study revealed a functional inversion by a CR regulator in driving gene reprogramming as an unexpected paradigm of tumorigenesis mechanism and demonstrated a high effectiveness of therapeutic targeting such switch.
The study was conducted to compare the growth performance of indigenous chickens and evaluate the effect of Enteromorpha prolifera (EP) supplementation on the growth of chickens. A total of 180 indigenous chicken ecotypes (Sinan, Dembecha, North Achefer, and Jawi) were used in the study. Chicken ecotype and sex had a highly significant (p < 0.001) effect on body weight and average daily gain (ADG). The highest final body weight (1811.5 ± 16.6 g) and ADG at twenty weeks of age (12.76 ± 0.12 g) were recorded for the Jawi ecotype, followed by the North Achefer. A significantly higher body weight and ADG in male chickens than female chickens were observed. The EP supplemented (EP +) chickens showed a significantly (P < 0.05) higher body weight and ADG than the non-supplemented (EP-) chickens. The interaction effect of ecotype and feed type was not statistically significant on body weight in the starter and grower phases, except at week 9. In the first four weeks, the highest (100%) and lowest (91.7%) survivability rates were recorded for the Sinan ecotype and the Jawi ecotype, respectively. In general, the Jawi and North Achefer ecotypes had better growth performance, and the Sinan ecotype relatively showed better survivability. EP supplementation could improve the growth performance of chickens.
Environmental exposure to the cadmium (Cd) has been shown to be a risk factor for colorectal cancer (CRC) progression, but the exact mechanism has not been fully elucidated. In this study, we found that chronic Cd (3 μM) exposure promoted the proliferation, adhesion, migration, and invasion of CRC cells in vitro, as well as lung metastasis in vivo. RNA-seq and TCGA-COAD datasets revealed that decreased hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit beta (HADHB) expression may be a crucial factor in Cd-induced CRC progression. Further analysis using qRT-PCR and tissue microarrays from CRC patients showed that HADHB expression was significantly reduced in CRC tissues compared to adjacent normal tissues, and low HADHB expression was associated with adverse clinical features and poor overall survival, either directly or through TNM stage. Furthermore, HADHB was found to play an important role in the Cd-induced malignant metastatic phenotype of CRC cells and lung metastasis in mice. Mechanistically, we discovered that chronic Cd exposure resulted in hypermethylation of the HADHB promoter region via inhibition of DNA demethylase tet methylcytosine dioxygenase 2 (TET2), which then led to decreased HADHB expression and activation of the FAK signaling pathway, and ultimately contributed to CRC progression. In conclusion, this study provided a new potential insight and evaluable biomarker for Cd exposure-induced CRC progression and treatment.
FIELD: soft drink industry. SUBSTANCE: invention relates to sanative mineral water that can be used as drinking water for course treatment in resort establishments and also for bottling. Invention is distinguished by following mineral composition, mg/cu.dm: calcium 400-650, magnesium 50-150, sodium+potassium 100-400, chloride 200-400, sulfate 1100- 2000, and bicarbonate 200-450. Total mineralization is 2.0-4.0 mg/cu.dm and pH 6.8-7.1. Water is cooled, filtered, disinfected, saturated with carbon dioxide, and bottled. For production of magnesium-calcium sulfate water, water from Lebedyansk water-bearing upper Devonian level from the depth 179-212 m. Invention enables using mineral drinking water for persons with chronic gastritis accompanied by normal and elevated secretory function of stomach, uncomplicated ulcer illness of stomach and duodenum, chronic diseases of liver and biliary ducts, chronic pancreatites and chronic diseases of urinary duct. EFFECT: improved sanative properties of water. 6 cl
The invention relates to the application of chloroform and ethyl acetate extract of Coreopsis tinctoria Nuff. to the preparation of medicaments or health foods for treating hypertension and hyperlipidemia, which belongs to the technical field of treatment of the hypertension and the hyperlipidemia. A method for preparing the chloroform and ethyl acetate extract of the Coreopsis tinctoria Nuff. comprises the following steps of: extracting the Coreopsis tinctoria Nuff. by using oil-soluble chloroform and ethyl acetate extraction solvents, and evaporating the organic solvents to obtain the chloroform and ethyl acetate extract of the Coreopsis tinctoria Nuff.. The chloroform and ethyl acetate extract of the Coreopsis tinctoria Nuff. can be used for preparing the medicaments for treating the hypertension and the hyperlipidemia, and also can be used for preparing the health foods for treating the hypertension.
Regulatory T (Treg) cells play a critical regulatory role in the immune system by suppressing excessive immune responses and maintaining immune balance. The effective migration of Treg cells is crucial for controlling the development and progression of inflammatory diseases. However, the mechanisms responsible for directing Treg cells into the inflammatory tissue remain incompletely elucidated. In this study, we identified BAF60b, a subunit of switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complexes, as a positive regulator of Treg cell migration that inhibits the progression of inflammation in experimental autoimmune encephalomyelitis (EAE) and colitis animal models. Mechanistically, transcriptome and genome-wide chromatin-landscaped analyses demonstrated that BAF60b interacts with the transcription factor RUNX1 to promote the expression of CCR9 on Treg cells, which in turn affects their ability to migrate to inflammatory tissues. Our work provides insights into the essential role of BAF60b in regulating Treg cell migration and its impact on inflammatory diseases.
On Day 2, 24 hours after the completion of standardized exercise, Group 2 subjects will apply ThermaCare HeatWraps in the same manner as described above for 8 hours. Subsequent heat wraps will be applied for 8 hours each at 48 and 72 hours after exercise (i.e., 3 applications in total).
Serotonin-norepinephrine reuptake inhibitors (SNRIs), including levomilnacipran, can precipitate serotonin syndrome, a potentially life-threatening condition. The risk is increased with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, meperidine, methadone, tryptophan, buspirone, amphetamines, and St. John’s Wort) and with drugs that impair metabolism of serotonin, i.e. MAOIs [see Contraindications (4), Drug Interactions (7.1)]. Serotonin syndrome can also occur when these drugs are used alone.

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). 

The concomitant use of levomilnacipran with MAOIs is contraindicated. In addition, do not initiate levomilnacipran in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. No reports involved the administration of methylene blue by other routes (such as oral tablets or local tissue injection). If it is necessary to initiate treatment with a MAOI such as linezolid or intravenous methylene blue in a patient taking levomilnacipran, discontinue levomilnacipran before initiating treatment with the MAOI [see Dosage and Administration (2.5, 2.6) and Contraindications (4), Drug Interactions (7.1)].

Monitor all patients taking levomilnacipran for the emergence of serotonin syndrome. Discontinue treatment with levomilnacipran and any concomitant serotonergic agents immediately if the above events occur and initiate supportive symptomatic treatment. If concomitant use of levomilnacipran with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms.
<P>PROBLEM TO BE SOLVED: To obtain an agent for suppressing bitter and astringent taste, widely applicable to various oral preparations in addition to foods and drinks having bitter or astringent taste and produced by using a new substance unknown by conventional technique as an active component.  <P>SOLUTION: This agent for suppressing bitter and astringent taste contains cyclofructan (CF) as an active component. The cyclofructan is cycloinuloheptaose and the agent is prepared in a manner to suppress the bitter or astringent taste of an oral application object having bitter or astringent taste by the addition of an active amount of cyclofructan. The agent has increased versatility to enable the wide application to various oral application objects in addition to foods and drinks having bitter or astringent taste. The agent suppresses disagreeable taste such as bitter taste, astringent taste, harsh taste and tannic taste felt in the case holding a food in the mouth without giving influence to the flavor of the food and gives good taste and flavor to the object to satisfy the taste by various persons from babies to aged persons.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Bipolar disorder is a severe and chronic mental illness that significantly increases mortality and greatly impairs functioning. Despite the use of pharmacological treatments, multiple acute episodes, long episode duration, and significant inter-episode sub-syndromal symptoms are common in patients with bipolar disorder. As a result, patients with bipolar disorder are symptomatically ill about half the time. There is clear evidence that the addition of psychotherapeutic interventions to medication management improves treatment outcomes, yet only about half of bipolar patients receive combined treatment. Current therapies also have limitations in terms of: 1) reliance on subjective patient self report and 2) difficulties in identifying warning signs of impending episodes. Furthermore, direct measurement of observable daily patterns of behavior is not routinely available, even though alterations in sleep and activity are core symptoms of bipolar disorder. Improving access to and long-term engagement in psychosocial interventions is needed to substantially improve treatment.

The investigators are developing a smartphone intervention that aims to make proven psychosocial interventions for bipolar disorder more readily and routinely accessible to patients as part of their day-to-day lives. The intervention, called LiveWell, will capture and feedback data about sleep and activity to assist patients in regularizing daily rhythms as well as help them monitor, recognize, and manage early warning signs of impending mood episodes. Behavioral and self-report data collected by the phone will also be used to provide clinicians with information regarding patient clinical status. This will increase patient-provider communication and allow for better evaluation and targeting of treatment.

Participation in the study will last 4 months. All participants will first undergo initial assessments that will include a telephone interview and a face-to-face interview with a certified study psychiatrist for the purpose of confirming diagnosis. Eligible participants will then be assigned randomly to the LiveWell or TAU group. Participants assigned to either group will be provided with a smartphone and wrist-worn device, and will be asked to carry the phones with them whenever they leave home and to wear the wrist-worn devices 24-hours a day 7 days a week. Participants assigned to the LiveWell intervention will be asked to undergo a 16 week psychosocial intervention consisting of phone-based self-monitoring and educational tools to help them learn skills to better manage symptoms. Participants assigned to the TAU group will be asked to provide limited self-report data on wellness and sleep. All participants, regardless of assigned group, will be asked to participate in assessments delivered over the phone to assess presence and severity of mood symptoms.
Investigators propose to use fMRI (functional Magnetic Resonance Imaging) to study CNS pain processing during the anticipation and experience of acute pain in individuals with FM and healthy controls. Investigators will recruit patients who are diagnosed with FM as well as healthy controls. After the baseline visit, FM participants will be randomly assigned into the CBT or control condition (Education). Overall, FM Participants will attend 8 treatment visits, and 6 assessment visits (two at baseline, one at mid-treatment, two at the end of treatment, and one at 6 months post-treatment). These assessment visits include a total of 3 fMRI sessions (at baseline, mid-treatment, and end of treatment). Healthy Controls will undergo the same baseline procedures as the FM subjects but will not attend any of the treatment or follow up assessment visits. Findings from this research will provide important information about catastrophizing's CNS (Central Nervous System) correlates.
The present invention relates to a compound traditional Chinese medicine preparation (weitasen) with the functionsstrengthening with tonics for replenishing qi to invigorate the spleen and relieving mental stress. The prescription of the components is 40 to 120g of ginseng, 200 to 400g of hawthorn fruit, 0.2 to 3.0g of vitamin B1, 0.2 to 3.0g of vitamin B2, 0.1 to 4.2g of vitamin B6, 0.9 to 3.0g of vitamin E, 1.0 to 3.2g of calcium pantothenate, 0.8 to 3.0g of nicotinamide and surplus supplementary materials by using 1000g as a weight unit, and sucrose or dextrin, honey and ethanol are prepared into a medical composition. The present invention can be directly used for preparing patent medicine and respectively extracting traditional Chinese medicine components in the composition to prepare various dosage form, such as granules, tablets, pills, capsules, oral medicinal liquid, medicinal powder, medical spirit and slurry. The present invention has good therapeutic effect on qi deficiency, and the treatment total effective rate is 95% for patients who suffer heart qi deficiency and hypofunction of the spleen. The present invention is suitable for general lassitude caused by deficiency of the heart-qi and spleen-qi, palmus, short breath, excessive sweating, sticky loose stools, poor appetite, postprandial abdominal distention or afternoon abdominal distention, etc. The present invention has the advantages of wide range of application, no toxic side effect and safe use.
RECOTHROM Thrombin topical (Recombinant), is a human coagulation protein produced via recombinant DNA technology from a genetically modified CHO cell line. RECOTHROM is identical in amino acid sequence and structurally similar to naturally occurring human thrombin. RECOTHROM precursor is secreted to culture medium as single chain form that is proteolytically converted to a two-chain active form (using a protein derived from snakes) and is purified by a chromatographic process that yields a product having hemostatic activities similar to native human thrombin. The cell line used to manufacture RECOTHROM has been tested and shown to be free of known infectious agents. The cell culture process used in the manufacture of RECOTHROM employs no additives of human or animal origin. The purification process includes solvent-detergent treatment and nano-filtration steps dedicated to viral clearance.

RECOTHROM is provided as a sterile, white to off-white, preservative-free, lyophilized powder in vials for reconstitution with diluent (sterile 0.9% sodium chloride, USP). Reconstitution with the provided diluent, as described [see Dosage and Administration (2.1)], yields a solution with a pH of 6.0 containing 1000 units/mL of recombinant thrombin for topical use. The formulated product is a clear, colorless solution upon reconstitution and contains the following excipients: histidine, mannitol, sucrose, polyethylene glycol 3350, sodium chloride, and calcium chloride dihydrate, USP.